Clinical Trials on VEGFC Protein in Non Small Cell Lung Cancer in Switzerland

Total 179 results

Centre Hospitalier Universitaire Vaudois

Recruiting

Personalized DC Vaccines in Non Small Cell Lung Cancer

Non-small Cell Lung Cancer

Switzerland
Philogen S.p.A.

Active, not recruiting

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer (Nivokin)

Non-small Cell Lung Cancer (NSCLC)

Switzerland
NovoCure Ltd.

Completed

NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Switzerland
TheraOp
AstraZeneca

Active, not recruiting

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC (PACCELIO)

Stage III Non-small Cell Lung Cancer | Locally Advanced | Unresectable

Switzerland
European Organisation for Research and Treatment...

Unknown

LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC (LungTech)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

Germany, Belgium, United Kingdom, Switzerland
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Terminated

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (ALERT-lung)

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

Ireland, Spain, Belgium, Italy, Netherlands, Switzerland
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients (salVage)

Non-small Cell Lung Cancer (NSCLC) | Stage IV

Switzerland
Kai-Uwe Schmitt, PhD, MEng, ICID

Recruiting

Digital Lifestyle Intervention for Lung Cancer Survivors After Inpatient Rehabilitation (QUALUCA)

Non-Small Cell Lung Cancer (NSCLC)

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Squamous-cell Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer

Switzerland
CureVac

Completed

Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Switzerland, Germany
Blueprint Medicines Corporation
Analysis Group, Inc.

Enrolling by invitation

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms... and other conditions

United States, France, Switzerland
Promontory Therapeutics Inc.
Pfizer; EMD Serono

Completed

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1)

Non-Small Cell Lung Cancer (NSCLC)

United States, Switzerland
Swiss Group for Clinical Cancer Research

Completed

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

NSCLC Non-small Cell Lung Cancer

Switzerland
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland
Novartis Pharmaceuticals

Recruiting

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Korea, Republic of, Spain, Japan, Germany, Switzerland
ETOP IBCSG Partners Foundation
AstraZeneca

Recruiting

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)

Non-small Cell Lung Cancer | Oligometastasis | Stage IV

Switzerland, Netherlands, Spain, Italy
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Spain, Singapore, Germany, Switzerland, Australia, France, Italy, United States
Martin-Luther-Universität Halle-Wittenberg
Radiation Oncology Working Group of the German Cancer Society

Completed

Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC

Non Small Cell Lung Cancer Stage III

Germany, Austria, Belgium, Spain, Switzerland
European Organisation for Research and Treatment...

Terminated

High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Lung Cancer

France, Switzerland, Belgium
ETOP IBCSG Partners Foundation
Hoffmann-La Roche; AstraZeneca

Active, not recruiting

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) (BOOSTER)

Non Small Cell Lung Cancer Metastatic

Ireland, Singapore, Spain, Switzerland, Korea, Republic of, Netherlands
ETOP IBCSG Partners Foundation
Amgen; Eisai Inc.

Withdrawn

AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC (AMBER)

Metastatic Non Small Cell Lung Cancer | KRAS G12C

Spain, Switzerland, Austria, Germany
ETOP IBCSG Partners Foundation
Bristol-Myers Squibb; Frontier Science Foundation, Hellas

Completed

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NICOLAS)

Non-small Cell Lung Cancer Stage III

Switzerland, Netherlands, Spain, Belgium, Germany
PharmaMar

Completed

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Head and Neck Carcinoma | Gynecological Cancer | Non-squamous Cell Lung Cancer

United States, Spain, Switzerland
ETOP IBCSG Partners Foundation
Janssen Pharmaceuticals

Recruiting

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)

Non Small Cell Lung Cancer

Spain, France, Switzerland, United Kingdom, Singapore, Italy, Netherlands
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Switzerland, Australia
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer

Lung Cancer

Switzerland
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Spain, Switzerland, United Kingdom
University Hospital, Geneva

Unknown

Lung Cancer Rehabilitation Study (LCRS)

Non Small Cell Lung Cancer

Switzerland
ETOP IBCSG Partners Foundation
European Organisation for Research and Treatment of Cancer - EORTC; Amgen

Terminated

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (SPLENDOUR)

Lung Cancer Non-small Cell Stage IV

Ireland, Spain, Switzerland, United Kingdom, France, Austria, Slovenia, Belgium, Italy, Germany, Poland
Swiss Group for Clinical Cancer Research

Completed

Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

Switzerland
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Non-Squamous Cell Non-small Cell Lung Cancer

United States, Germany, Hong Kong, Spain, Australia, Mexico, Austria, France, Singapore, Switzerland, Canada, Poland, Argentina, Brazil, Chile, Czechia, Hungary, Italy, Norway, Peru, Romania, Russian Federation
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
Swiss Group for Clinical Cancer Research

Completed

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Switzerland
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

Non-Squamous Non-Small Cell Lung Cancer

United States, Italy, Canada, Austria, Finland, France, Greece, Korea, Republic of, Panama, Portugal, Spain, Turkey, United Kingdom, Taiwan, Brazil, Germany, Poland, Chile, Guatemala, Russian Federation, Switzerland, Thailand, Ukraine, Serb... and more
Swiss Group for Clinical Cancer Research

Active, not recruiting

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Non-small Cell Lung Cancer | Malignant Pleural Mesothelioma

Switzerland
Hoffmann-La Roche

Completed

AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

France, Germany, Spain, Sweden, Russian Federation, Greece, Switzerland, Korea, Republic of, Italy, Netherlands, Turkey, United Arab Emirates
Iovance Biotherapeutics, Inc.

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States, Canada, Germany, Netherlands, Switzerland
GlaxoSmithKline

Completed

Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer

Netherlands, Finland, Taiwan, Belgium, Canada, Israel, Poland, Spain, Australia, Singapore, Latvia, Thailand, United Kingdom, Germany, Italy, China, Russian Federation, Philippines, Austria, Greece, Hungary, Denmark, France, Ukraine, Li... and more
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Non-small Cell Lung Cancer

United States, Germany, Spain, Japan, Canada, France, Korea, Republic of, Italy, United Kingdom, China, Taiwan, Hungary, Singapore, Switzerland, Netherlands, Brazil, Mexico, Russian Federation, Puerto Rico, Poland, Hong Kong, Romania and more
Cellectar Biosciences, Inc.

Completed

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Non Small Cell Lung Cancer

United States, Israel, Canada, Spain, Russian Federation, Serbia, Italy, Poland, Romania, Switzerland, Ukraine, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
UNICANCER

Completed

Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung Cancer

France, Switzerland, United Kingdom
AbbVie

Active, not recruiting

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Australia, Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland and more
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) (START)

Non-small Cell Lung Cancer

United States, Sweden, Australia, Czech Republic, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Germany, China, Poland, Romania, Denmark, Hong Kong, Canada, Austria, Belgium, Hungary, Israel, Nether... and more
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Canada, Belgium, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Poland
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more

Clinical Trials on VEGFC Protein in Non Small Cell Lung Cancer in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations